Gastroenterology and Hepatology最新文献_第9页

Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. 3期ESSENCE试验：西马鲁肽治疗代谢功能障碍相关脂肪性肝炎

Gastroenterology and Hepatology Pub Date : 2024-12-01

引用次数: 0

The Potential Role of Hyperbaric Oxygen Therapy in Patients With Inflammatory Bowel Disease. 高压氧治疗在炎症性肠病患者中的潜在作用。

Gastroenterology and Hepatology Pub Date : 2024-12-01

Parambir S Dulai

引用次数: 0

Highlights From the Joint AGA/ACG Guideline on Pharmacologic Management of Chronic Idiopathic Constipation. 慢性特发性便秘的药物管理AGA/ACG联合指南的亮点。

Gastroenterology and Hepatology Pub Date : 2024-11-01

Lin Chang

引用次数: 0

Management of Suboptimal Response in Primary Biliary Cholangitis Treatment. 原发性胆道胆管炎治疗的次优反应管理。

Gastroenterology and Hepatology Pub Date : 2024-11-01

Gideon M Hirschfield

引用次数: 0

Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment. 酒精使用障碍和酒精相关肝脏疾病：新定义、筛查和治疗

Gastroenterology and Hepatology Pub Date : 2024-11-01

Giovanni A Roldan, Christopher Tricarico, Robert S Brown

{"title":"Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment.","authors":"Giovanni A Roldan, Christopher Tricarico, Robert S Brown","doi":"","DOIUrl":"","url":null,"abstract":"Alcohol-associated liver disease (ALD) poses a significant global health burden and is a leading cause of liver-related morbidity and mortality. ALD encompasses a spectrum of disease states ranging from asymptomatic steatosis to acute hepatitis and cirrhosis. Alcohol use disorder (AUD) significantly increases the risk of developing ALD, and insight into AUD can provide a more complete understanding of ALD and the patients affected by these interrelated diseases. Accurate and timely identification of AUD, even in primary care, through validated screening tools combined with blood tests and imaging techniques facilitates early detection of ALD. Although liver transplantation (LT) remains the most effective treatment for end-stage ALD, patient outcomes post-LT have evolved because of shifting perspectives on ALD transplant eligibility, comprehensive pre-LT evaluations, and advancements in post-LT ALD detection. Nonetheless, addressing disparities in LT practices for ALD is paramount for ensuring equitable access to this life-saving intervention. This article offers an updated synopsis of ALD definitions, screening methodologies, and contemporary management approaches, particularly in the context of LT.","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 11","pages":"662-671"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Noninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis. 无创评估识别高危代谢功能障碍相关脂肪性肝炎患者。

Gastroenterology and Hepatology Pub Date : 2024-11-01

Markos Kalligeros, Pojsakorn Danpanichkul, Mazen Noureddin

{"title":"Noninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis.","authors":"Markos Kalligeros, Pojsakorn Danpanichkul, Mazen Noureddin","doi":"","DOIUrl":"","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease, is a major global health issue and a leading cause of chronic liver disease. The prevalence of MASLD is increasing globally, with the disease in some patients progressing to metabolic dysfunction-associated steatohepatitis (MASH), which significantly raises the risk of fibrosis, cirrhosis, and adverse outcomes. Accurate identification of patients with at-risk MASH, defined as MASH with a fibrosis stage of 2 or higher, is critical for timely intervention and management. Although liver biopsy remains the gold standard for diagnosing MASH, its invasive nature, potential complications, and variability in interpretation necessitate the implementation of noninvasive tests (NITs). NITs hold the potential for reducing reliance on liver biopsies, enhancing early diagnosis, and improving patient management of chronic liver disease. Continued research and validation are essential to optimize these tools for clinical application. This article explores current NITs, including imaging biomarkers, combined imaging and serum biomarkers, advanced biomarkers and composite scores, as well as artificial intelligence-based approaches, which also show promise in improving the accuracy of noninvasive at-risk MASH detection.","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 11","pages":"672-677"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring Alcohol Use Disorder and Alcohol-Associated Liver Disease. 探索酒精使用障碍和酒精相关肝脏疾病。

Gastroenterology and Hepatology Pub Date : 2024-11-01

Gary R Lichtenstein

引用次数: 0

Early Surgery for Patients With Ileal Crohn's Disease. 回肠克罗恩病的早期手术治疗

Gastroenterology and Hepatology Pub Date : 2024-11-01

Geert D'Haens

引用次数: 0

Highlights From the Recent AASLD Practice Guidelines on Noninvasive Assessment of Hepatic Fibrosis and Steatosis. 美国肝脏病学会（AASLD）近期发布的肝纤维化和脂肪变性无创评估实践指南要点。

Gastroenterology and Hepatology Pub Date : 2024-10-01

Richard K Sterling